Why the diagnosis must be specific
Interstitial lung disease is a broad category. Idiopathic pulmonary fibrosis, connective-tissue-disease-associated ILD, hypersensitivity pneumonitis, occupational disease and other fibrotic patterns differ in cause, prognosis and standard treatment.
A regenerative programme should not accept the phrase “lung fibrosis” without reviewing HRCT pattern, specialist diagnosis, disease progression and whether the underlying cause is controlled.
What a regenerative pathway may involve
Lung-cell research does not establish a universally available treatment for pulmonary fibrosis. RMC has not verified current clinical authorisation and international intake for this proposed use. A specialist must review the precise ILD diagnosis and the proposed product.
The respiratory team must determine whether the subtype and stage fall within the intended pathway and whether standard therapy has been appropriately considered.
Records needed for a meaningful review
- ILD or pulmonology specialist diagnosis
- High-resolution CT report and image files
- Serial pulmonary-function tests, especially FVC and DLCO
- Oxygen requirement and exercise testing
- Autoimmune and connective-tissue-disease work-up where relevant
- Exposure, occupational and medication history
- Current antifibrotic, immunosuppressive or other treatment
- Exacerbations, infections and hospital admissions
The reviewing institution may request additional tests after seeing the initial case summary.
Questions that affect eligibility
- What is the exact ILD subtype and HRCT pattern?
- How fast has lung function changed?
- Is there an autoimmune or exposure-related cause?
- Is the disease stable enough for elective treatment?
- Is the patient taking antifibrotic or immunosuppressive medication?
- Would transplant or another specialist pathway need consideration?
Evidence and limitations
Early and mid-stage research in organ-specific lung-cell approaches is clinically important, but evidence must be interpreted by indication and stage. A case series or phase II result does not prove benefit for every form of ILD.
Patients should ask whether the programme measures FVC, DLCO, exercise capacity, imaging, symptoms, exacerbations and survival, and how long follow-up lasts.
Other treatment options to consider
Depending on subtype, evidence-based care may include antifibrotic medication, immunosuppression, exposure avoidance, oxygen, pulmonary rehabilitation, vaccination, transplant evaluation and management of reflux or infection. A regenerative review should complement, not replace, appropriate ILD care.
Next step for an international patient
Provide the exact ILD diagnosis, recent HRCT, serial FVC/DLCO, oxygen use and current medication. We can identify whether a formal pathway review appears reasonable.
Do not stop prescribed treatment, make irreversible travel plans or pay a medical fee until the responsible institution has reviewed the case and issued written instructions.